Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : BCRX: Target practice for shorts -- Ignore unavailable to you. Want to Upgrade?

To: Wolff who wrote (90)	11/3/1999 9:56:00 AM
From: arpad toth	Read Replies (1) \| Respond to of 96

Looks like some buying going on! volume over 225k. ps. over 330k

To: Wolff who wrote (90)	11/3/1999 10:04:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 96

And on the other side of the equation, if disclosures allowed such, it might read....... On the other hand, multinational pharmas are willing to test the size of the market for neuraminadase inhibitors, and it looks as though we would have, given successful completion of our clinical program, the only molecule with once daily dosing. I don't own this company. IMO, there are better risk:reward ops in biotech. You don't, however, attempt to provide balanced analysis.